Escalon(R) Medical Corp. Completes Bolt-On Acquisition, Enhances Market Position in France and Expands Produc...(egies improve upon the operations of the...),Health

Date:1/6/2009

egies, improve upon the operations of the Company business units, including the ability to make acquisitions and the integration of any acquisitions it may undertake, if any, of which there can be no assurance,

implement cost reductions,

generate cash,

identify, finance and enter into business relationships and acquisitions, and make timely payments for any financing, and

new product development, commercialization, manufacturing and market acceptance of new products.

Other factors include uncertainties and risks related to:

• marketing acceptance of existing products in new markets,
• research and development activities, including failure to demonstrate clinical efficacy,
• delays by regulatory authorities, scientific and technical advances by the Company or third parties,
• introduction of competitive products,
• ability to reduce staffing and other costs and retain benefit of prior reductions
• third party reimbursement and physician training, and
• general economic conditions.

Further information about these and other relevant risks and uncertainties may be found in the Company's reports on Form 10-K for year ended June 30, 2008 and Form 10-Q for the quarter ended September 30, 2008, and its other filings with the Securities and Exchange Commission, all of which are available from the Securities and Exchange Commission as well as other sources.

'/>"/>

SOURCE Escalon Medical Corp. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3
Related medicine news :

1. Escalon(R) Reports Financial Results for 2007 Fiscal Year
2. Escalon(R) Reports First Quarter Fiscal 2008 Results
3. Escalon(R) Announces FDA 510(K) Clearance for D3 Hematology System
4. Escalon(R) Announces Executive Promotions
5. Escalon(R) Announces China Registration for Sonomed PacScan(R) and E/Z-Scan(R) Series of A-scan, Pachymeter and B-Scan Systems
6. Escalon(R) Enhances Position Within IVD Reagent Market with Strategic Acquisition of JAS Diagnostics
7. Escalon(R) Receives FDA 510(k) Clearance to Market the LIASYS(TM) Clinical Chemistry and Immunoturbidimetric Analyzer
8. Escalon(R) Reports First Quarter Fiscal 2009 Results
9. Escalon(R) Medical Corp. Completes $1.1 Million Private Equity Financing
10. MSU engineering team designs innovative medical device
11. ATS Medical to Present at the 2007 Thomas Weisel Partners Healthcare Conference